Showing 1991-2000 of 3462 results for "".
New products and pharmacologic developments
https://practicaldermatology.com/columns/new-products/new-products-and-pharmacologic-developments/21688/Evaluating Hyaluronic Acids in Patients with Skin of Color
https://practicaldermatology.com/topics/general-topics/1109_05-php/22057/One expert places new findings in perspective and explains why new data on fillers in skin of color are essential.Seborrheic Dermatitis Update: A Review of the Etiology and Treatment of Seborrheic Dermatitis
https://practicaldermatology.com/programs/practical-dermatology/seborrheic-dermatitis-update-a-review-of-the-etiology-and-treatment-of-seborrheic-dermatitis/24003/Seborrheic dermatitis (SD) is an inflammatory skin condition that often involves flaky, erythematous patches on sebum-rich areas of the body such as the face and scalp.1 At least 50 million Americans have a form of seborrheic dermatitis on the scalp, more commonly known as dandruff. SD presents in aLook to the EAST: Shared Decision Making in the Era of New Therapies
https://practicaldermatology.com/topics/atopic-dermatitis/look-to-the-east-shared-decision-making-in-the-era-of-new-therapies/23372/Assessing Efficacy, Accessibility, Safety, and Tolerability is the key to a meaningful dialogue with patients.The Microbiome: What Do We Know Now?
https://practicaldermatology.com/topics/atopic-dermatitis/the-microbiome-what-do-we-know-now/23122/Questions and answers about the microbiome and its role in influencing cutaneous health.How Air Pollution Affects the Skin
https://practicaldermatology.com/programs/practical-dermatology/how-air-pollution-affects-the-skin/24041/An Interview with Dr. Mark Birch-MachinStaying Ahead of the Curve
https://practicaldermatology.com/topics/practice-management/staying-ahead-of-the-curve/20882/Is your practice website responsive enough?The Hidradenitis Suppurativa Therapeutic Pipeline
https://practicaldermatology.com/topics/rare-disease/the-hidradenitis-suppurativa-therapeutic-pipeline/54824/Though treatment options are currently limited, the pipeline for HS therapeutics is active with numerous medications in development.Psoriasis, Biologics, and Cardiovascular Disease: The Heart of the Matter
https://practicaldermatology.com/topics/psoriasis/psoriasis-biologics-and-cardiovascular-disease-the-heart-of-the-matter/23215/A relationship between increased cardiovascular events in patients with psoriasis has implications for management of this chronic disease.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-39/23790/